Dr. Hope S. Rugo on the SOPHIA Trial in HER2+ Breast Cancer
Cancer Network spoke with Hope S. Rugo, MD, of the University of California, San Francisco, about the results of the phase III SOPHIA trial in HER2-positive breast cancer.
Cancer Network spoke with Hope S. Rugo, MD, of the University of California, San Francisco, about the results of the phase III SOPHIA trial in HER2-positive breast cancer.
Recent Videos
Related Content
Giredestrant Combo Yields Positive PFS in Subgroups After CDK4/6i in ER+/HER2– Breast Cancer
December 13th 2025Article
“The magnitude of clinical benefit was clinically meaningful and consistent, and was regardless of PIK3CA mutations or alterations in the PIK3CA pathway, duration of prior CDK4/6 inhibitors, including patients who progress within 6 to 12 months, and the choice of prior CDK4/6 inhibitors,” said Hope S. Rugo, MD.
